Pursuing Aggressive Advocacy With SparingVision's Stéphane Boissel
SparingVision President and CEO Stéphane Boissel did not get his start in the biotech sector – a former financial consultant and venture capitalist, Boissel joined SparingVision in August 2020. But this move was far from his first go-around in biotech: with over 25 years of experience in the sector across a range of functions, from corporate finance to strategy to business development, Boissel has helped shape the success of companies like TxCell USA, Genclis, Innate Pharma, and Transgene.
In a recent episode of The Business of Biotech, Boissel sat down to talk about his approach to SparingVision’s growth strategy, as well as how it’s making progress in its pursuit of gene therapies to address inherited retinal diseases like retinitis pigmentosa (RP).
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.